Right. Good afternoon, everyone. Thank you for joining us on the last day of the Jefferies Global Healthcare Conference in London. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have this day, the management team of Vicore Pharma. On stage with me is Ahmed Mousa and Bernt. Bernt, I'm not going to butcher your last name, so we'll just go with that.
Of course.
Really appreciate you guys making the time to come out here today and tell us about the Vicore story. Ahmed, can I pass to you just for some opening remarks, if you can introduce yourself and the company?
Yeah, absolutely. Thanks for having us, Faisal. It's great to be here. Ahmed Mousa, CEO of Vicore Pharma. Vicore is a company that's historically a European company traded on the Stockholm Exchange, now listed in the U.S. as well as we grow the audience in the U.S. certainly for idiopathic pulmonary fibrosis, the lead indication we're working on. The U.S. is quite a large market. Vicore has really been advancing a unique biology in this space that we think can drive a potent resolution of fibrosis effect. It's within the angiotensin II pathway, and it's agonism of a target called the angiotensin II type 2 receptor. Idiopathic pulmonary fibrosis, the disease that we're working on, is a really tough one with only three to five-year survival. We're very excited to have a unique approach in this space and a molecule in late-stage development for it.
Great. Thank you, Ahmed. Let's get right into the data that you've generated so far for buloxibutid, and then we can get into the catalyst coming up. In terms of the phase II-A AIR data that you have, it's a little bit unique in that it's a single-arm study, which is a little bit atypical in IPF. I think when we first met, I told you, these results look almost too good to be true. Can you help kind of put those data into context and sort of explain what that data tell us?
Yeah, absolutely. I think that, right, as many might know, in pulmonary fibrosis, in particular in IPF, there have been many earlier trials that have not translated into success in later-stage trials. We believe that one of the reasons for that is many of the earlier-stage trials are only 12 weeks or only three-month trials. Many mechanisms in this space can have an anti-inflammatory effect, so you can reduce swelling, and that might give you a temporary and early increase in lung capacity, FVC, which is the key measurement in this space. But that gets overtaken by continued pro-fibrotic drive over time. We've seen companies where you kind of see a little pop in the lung function, and then unfortunately, it declines.
I think this is one of the kind of key risks that our phase II-A dataset kind of accounts for, in the sense that you have nine-month data, and you see what this drug does over that time period. The second piece of the puzzle, I would say, is that nine-month time period also tells you about safety and tolerability. There have been a number of therapies where, again, three-month treatment has not shown a toxicity profile or a detrimental effect on lung function, and then when you look longer, actually, the drug might be doing harm rather than doing good. I think, again, that's something we've clearly de-risked in our phase II-A dataset, but also that we've clearly de-risked with the recent futility readout as well. I think the last piece of the puzzle is the signal that I think is present in the phase II-A dataset.
I think the notion of the dataset being too good to be true depends on how you interpret it. I would say at Vicore, how we interpret it is a clear signal of clinical activity. IPF patients have decline in lung function. If you have IPF patients, they don't have stable lung function. It is a, unfortunately, very progressive disease. The level of decline can be variable, but over a nine-month period, the percentage of patients you would expect to have stable or improved FVC would be in the single digits. I think what we show here is quite impressive in terms of a signal of clinical activity.
Candidly, in a place like IPF where the unmet need is so high and the bar is so low, it is, I think, a great setup for our phase II-B study, which is, I think, the largest phase II ever run in IPF, which will clearly show us the effect size kind of signal. I think that that's kind of how we interpret the phase II-A dataset and why it gives us a lot of excitement as we move forward.
Got it. I think you guys have done some pretty interesting things to sort of kick the tires on the phase II-A and evaluate the robustness of the FVC signal that you saw there. Can you tell us a little bit about this? I think you did some interesting external control analysis. Then, Bernt, you were talking that you guys had looked very closely at every single patient as well. Can you talk about both of those?
Yeah, absolutely. I think the interesting context of the AIR study is it was a single-arm open-label study, but it was pre-specified that we would compare against historic controls from the INPULSIS study, where we know that this is a relentless progressive disease. We know there is a decline of about 180 ml over the nine months that we run this study over. What we did is that we just didn't look just at the patients who completed. We also looked at the entire dataset, imputing very conservatively patients who discontinued as if all of those had progressed. We know from our data that's not the case. We had actually predefined that if there were signs of progression according to predefined thresholds for FVC decline, they had to be taken out. Only three out of the 52 patients randomized were taken out of that.
But again, we took a very conservative stance, imputed as if all discontinued patients were progressors, and then we still saw some improvement. Of course, more modest with this conservative imputation method than the completer analysis. But I think, yeah, hugely encouraging compared to what we know from the disease. In addition, we also did a post-hoc analysis where we actually matched, using a large external control arm set, we matched our patients to external data and saw again what we expected, decline in those patients. Then we compared our data set to the external control set, and basically what that tells us that the probability that we would find data as in AIR is really very small. That is just by mere chance.
This really gives us confidence that there's a true clinical signal, and I think has given us the confidence to run this really large, global, robust placebo-controlled clinical trial that we're currently running.
Got it. Yeah, I think that's a really important point that you made, that the phase II-B that you're running is essentially almost a phase III study in everything but sample size, basically, right?
Yeah, I think it is. I mean, it's the primary endpoints, FVC is 52 weeks. We're doing the dose ranging that's sometimes deferred to a phase III. So, we are really confident that this will count as one of two well-controlled studies, and we will only need one phase III study after this, yeah.
Got it. Interesting. Is that something that you guys have spoken to regulators about, or do you have to wait for the data to then kind of check with them if this would be accepted as a pivotal? I know the design is pivotal-like, though.
I think this will be at a phase II discussion point. Everything we have seen as a precedent from all the drugs that have been developed so far in IPF really supports this also in consultation with prior pulmonary department leads from FDA really supports our position here.
Got it. Most investors will be aware that IPF has been a really tricky space for drug development, both from a biology perspective, but also from a trial execution perspective. With respect to running the phase II-B ASPIRE study, can you talk about the execution in the study and what you guys have done to ensure that you have a robust outcome here?
Yeah, absolutely. IPF trials are, on one end, complex because these are older patients with lots of comorbidities. On the other hand, the field has become hugely accustomed to doing these trials, so we are not inventing the wheel. Our method of working is that we provide very close oversight. We are very close to the sites, so we call these investigators ourselves to make sure we have really high-quality data, both from a safety tolerability. We do not want to miss anything, and so far the data look really good. No unexpected safety tolerability signal.
Most importantly, we want to make sure that our primary endpoint data are of the highest quality, reducing the variability, which will give us additional power to detect also smaller effect sizes, which we think are still hugely clinically relevant, some of the learnings in the recent drug development in IPF.
Got it. With respect to what you've been able to observe in the blinded data from the study with respect to blinded safety, with respect to variability, things like that, can you comment how those things are tracking and how that compares to your ingoing expectations and what's been seen in the landscape?
Yeah, absolutely. I think maybe first safety tolerability, I think one of the unique things about buloxibutid is overall it's really safe and well-tolerated based on all the data we have from completed studies, our blinded review of the data, but also the four independent DMC meetings we've had so far that have recommended to continue the study without any modification. That really gives us a high level of confidence in the drug's safety and tolerability profile. There's one expected tolerability finding, which is hair loss. Overall, that has been well-tolerated in the sense that only very few patients discontinued with it. It hasn't hampered enrollment. Also not, for example, for female participants. We've enrolled a proportion of female participants in line with all other phase III studies. Again, particularly in this life-threatening disease, predominantly in elder males, it does not appear to be an issue.
Got it.
Of course, we're also looking at not just quality of FVC, really driving that, having people on the ground to make sure we do the right thing. I think looking at the blinded data, I think we're seeing the effect there, our variability, as measured by standard deviation, is within our going-in assumption. I think that's a good sign, and I think would set us up well to detect relevant benefit for patients.
Great. Just remind us, you had upsized the study before completing the enrollment. What is the study now powered for after the upsizing?
Yeah, so we initially powered the study to detect an effect size of 125 ml, which was, I think, a conservative effect size based on the AIR data. We didn't assume a huge increase. We then saw, of course, that there was a huge enthusiast for much more effect sizes, so increased the sample size to be able to detect smaller effect sizes more towards the range of treprostinil. That doesn't mean we won't be able to detect even smaller effect sizes. I think with the sample size and the variability we're currently tracking, we should be well able to get statistical significance smaller effect sizes in the range of nintedanib.
Got it. Okay, so at the sample size that you're now at, you think that even at, like, I believe nintedanib is 70 ml, 80 ml range, you believe you'd be able to declare a stat sig on that based on the powering and based on the variability that you're observing?
Yeah, I think that's our fair assumption, yeah.
Got it. Okay. The new piece of info this year as well, in addition to the strong execution and completing the enrollment, is the disclosure of the baseline characteristics in the study. You mentioned you had a decent proportion of women enrolled in the study as well. Can you talk about what else you're seeing with respect to the geographic mix and the mix of patients and background therapy?
Yeah, absolutely. We're really happy with the profile of the patients we enrolled. I think it supports we have enrolled a patient population that's really broadly representing patients with IPF, both from a geographical position, nicely distributed across APAC, Europe, the U.S., 25% in the U.S., but also their overall profile in terms of lung function deficit very close to recent phase III studies. I think one point I think is interesting to highlight, we enrolled about 40% patients not on background therapy. We were aiming for at least 30%, so we really reached that goal. Why do we think it's important? Well, one, of course, we want to make sure we look at robustness and consistency effect across patients on and not on background therapy, while in former phase III.
Importantly, we think it will also potentially help us position this drug as a first-line treatment. I think it's interesting to note that 25% of all patients are actually treatment naive. As we see that the treatment paradigm is still really focusing on monotherapy, right? Everyone wants to do combination therapy, but there's no combination therapy that's well-tolerated. Monotherapy is still really important, and I think we're well-positioned. Maybe tagging onto that, as I mentioned, our drug is really well tolerated. We're also not seeing an unexpected tolerability issue in combination with nintedanib based on blinded data, preliminary blinded data in our study. I think that's hugely important because obviously the field want to go there. This is a difficult disease.
If we really want to make a large impact, it might mean we need to combine, and then I think buloxibutid really has unique attributes.
Got it. With respect to the patients who are not on background therapy, obviously in IPF, it's a very tough disease, tough prognosis, but the drugs are also not very good. What you see in the landscape is that it can be somewhat unpredictable. Those patients who are not on background, are those patients kind of better prognosis, worse prognosis, because it's a very individualized kind of treatment decision. Based on what you observed on the baselines, on the intersection between prior treatment exposure and baseline lung function, what is kind of the relationship that you're seeing? Are those patients, the 40% who are not on background, are they any kind of better or worse prognosis than the remaining patients?
Yeah, I think that's sort of an ongoing learning in the field. Here, I think we need to discriminate between what's happening in real life and those patients who choose to go into a clinical trial. Because obviously patients who are on standard of care, doing really well, are not very motivated to be in clinical trial, and that's, I think, what we're seeing. Patients on background therapy overall have a quite large decline in FVC, translating maybe in a bad prognosis. Reverse seems also to be true. Patients not on background therapy seem to do relatively a little bit better than you would expect based on the hypothesis. But here, I think it's a little bit more complex because the patients not on background therapy is a mix.
Patients who are treatment naive and may have or may not have access to therapy, and those who had prior exposure to, for example, nintedanib, pirfenidone, did not really tolerate it well, felt overall pretty good, and thought, "I don't want those drugs that I don't tolerate. Let me try a clinical trial." I think the main message here for us is that both these patient populations and in combination, unfortunately still have a large FVC decline, I think highlighting the urgent unmet need, but also giving us, I think, a very large window to show the benefit of buloxibutid in our trial. So we're really very confident about that we'll be able to do that.
Got it. Then you recently had a futility analysis that you successfully passed in the study. Just for the investors who are listening, can you just remind folks what the assumptions were going into that futility analysis, and importantly, what was kind of the minimum threshold that you had to clear to be able to successfully meet the criteria of being non-futile?
Right. I think the most important thing is this futility analysis was really there to protect patients. This is one of the tools for the IDMC to make sure that if buloxibutid has no effect or particularly had a detrimental effect, we would not continue, and we see this as a really meaningful de-risking step in this landscape. The number of trials that have failed because of safety, Pliant, the ISABELA study from Galapagos, Galecto, one of their arms, is really relatively quite high. So passing this hurdle, protecting the patient, I think has really been an important step. How did we do that? The first 100 patients who had completed the 52-week treatment period or discontinued in the time point were analyzed, and then we compared the high dose versus the placebo patients.
If those patients, if that trajectory predicted that the chance of having a positive study was less than 20%, then sort of phrased as the conditional power of 20%, we would stop the study. If you do the math, which of course the statisticians do, that means that in fact the study would only be stopped if buloxibutid patients would do worse than patients on placebo. I think that is a logical step for a phase II where we're at, because it's really difficult to do a really efficacy interim, because by the time you have enough data to say there is efficacy, you're near completion of the study and you just need to complete the study.
Got it. Yeah, I think that's something that I totally get your point. It's more of a patient safety thing, but unfortunately from the Wall Street side, then it doesn't tell us too much.
Although my real pitch would be here that, right, what we know is that well-tolerated therapies are something where there's a super high desire, and everything we have, including these DMC interactions as well as the futility framework, really underscore that. I think that goes back to the uniqueness of the biology, right? IPF is a disease where the lungs become injured, the air sacs become injured, and then there's the scarring. Most mechanisms are trying to block the fibrotic process, even though, of course, when you block that process, you can interfere with normal tissue homeostasis. That's the reason why the programs that Bernt mentioned where there were toxicities, right, I think that was associated with the biology.
To instead have this biology where you are trying to repair the injured cellular compartments, right, and then you are seeing consistent with that a nice profile from a safety and tolerability perspective, I think that really comes back to kind of the advantage of this mechanism of action. I think that also gives you huge benefits on the efficacy side, right? One, you are able to show a broad range of effects and still have a very attractive therapy because your tolerability is good. But two, this is a landscape where people want to go into combination therapy, and this is a unique mechanism, right, distinguished from those who are kind of more downstream and blocking the fibrotic cascade. We think that is a really nice opportunity for us to play well with the current therapies as well as those that might come along in the future.
Got it. That is helpful. Then, Ahmed, there are two questions that I wanted to ask you in our last few minutes here. So one, you recently did the NASDAQ listing as well. I know you are getting in front of a lot of more U.S. investors as well. This data next year, kind of broadly seen as a very high reward, high risk, big binary catalyst. Among the investors who have been able to come around and convince themselves that this has a good shot at working, what have you perceived has been the light bulb moment for investors to come around and really believe?
Yeah, I think that when you are talking about tough multifactorial diseases like IPF, you also then have to get your evidence from multiple angles, right? So if you look at the mechanism, look at the translational data, which candidly for this molecule is incredibly strong, right? We show efficacy on the epithelium, we show efficacy in the interstitium, the fibroblast compartment, and we show efficacy on the vasculature, right? Similar data to TYVASO in pulmonary hypertension models like the Sugen hypoxia model and the monocrotaline model. You realize that this is kind of a pleiotropic effect mechanism of action, and there is really nice data backing up what we are able to do, and it is very consistent with what the field believes is the key to this disease. So now there are actually a lot more in the preclinical and early clinical stage epithelial targeting therapies.
Then I think the second point becomes placing the phase II-A data within that context, right? Taking the pieces that add to the conviction while understanding that the study, as all studies do, have limitations. I think that what we learned in this field is that even though it can be attractive to get conviction on placebo-controlled 12-week data, I think we have already seen that that is a high-risk proposition. So my view would be, open label nine-month data could actually be more attractive in the context of a disease state like this, and I think that is the type of perspective that investors who have gotten comfort have taken.
Got it. I think that was something that stood out to us as well when we were doing the work on this. Remind us, when are you guiding for data for the phase II-B?
Yeah, we plan to have a readout in the middle of next year. We announced when we enrolled our last patient, which was around late April of this year.
Got it. Within the pulmonary space, two of the big meetings for IPF data disclosures, we have ATS in May and ERS in the September timeframe. A very active competitive landscape here. I assume at ATS we will see data from the admilparant phase III study. I assume we may see the taladegib phase II readout as well. Among those two readouts and others that we might see in the next six months or so, what are you looking for within the competitive landscape, and how do you feel about the opportunity that exists for you?
Yeah. First, we continue to be very excited about the opportunity, and again, how we're positioning this therapy is something that you can take alone, right? And we have a 40% of our enrolled population not on background, as Bernt mentioned, and on top of other therapies. And so certainly we're looking very closely in particular at the admilparant phase III readout. We're looking forward to seeing that dataset, and certainly if that's a therapy that ultimately looks attractive and becomes approved, we would look for in our phase III development at the opportunity to combine with them, which again, we think mechanistically could be very complementary, and certainly could make our therapy a very attractive combination partner.
Got it. With respect to the other thing that's been unique here with respect to combinations that you're saying is the drug-drug interaction profile, given that some of these, we can call it, I guess, conventional antifibrotics can be bad actors from a DDI perspective. Can you talk about the de-risking work that you've done there?
Yeah, absolutely. We've done direct DDI de-risking work with nintedanib and pirfenidone in the clinic to date. There is a DDI risk with pirfenidone, so for that reason, it's excluded from the phase II-B. Ultimately, there could be pathways towards allowing combination with lower doses of pirfenidone, because essentially the combination would elevate the level of peripheral pirfenidone expression if you were to take them both at the indicated doses. We do not anticipate, although we have not fully confirmed issues with admilparant, we've already allowed nintedanib background in our phase II-B trial, and that's based on what we know. There are a few more things we'll do there, but we generally think that we'll combine well with them. Of course, we're confirming on TYVASO. Again, we anticipate there will be the ability to combine absent some surprises in future datasets.
Here, we try to develop strong datasets behind all of these because, of course, DDIs, particularly when you have some of these standard of care therapies with low therapeutic windows, so if you change it could significantly change the tolerability profile, have an effect, and that's why we also want to be careful and thoughtful as we do that. We ultimately think this will be an attractive therapy that's broadly combinable.
Great. The IPF market recently saw its first new drug approval in quite a while. Based on our discussions with physicians, it seems like the uptake of that therapy, nintedanib, is going quite robustly. Is that what you're hearing as well from the physician community, and what do you think that tells you about the market?
Yeah, I think we've seen both massive excitement and significant frustration. I think the massive excitement comes from a better tolerated therapy, less GI side effects than nintedanib. I think what it underscores is that excitement is notwithstanding relatively incremental effect, which may be, there's no direct study on this, which may be in line with the prior standard of care. Something is very attractive to clinicians if it's better tolerated, notwithstanding relative effect size. I think the frustration comes from the inability to unlock combination therapy. The clear desire of clinicians here is to develop the idiopathic pulmonary fibrosis landscape to a place where it's similar to pulmonary hypertension. Because the three available therapies currently have a GI side effect profile, clinicians have found it challenging to combine them with each other.
I think the availability of new well-tolerated therapies that don't have that GI profile, such as buloxibutid, our therapy, we think could be a really nice place in the ultimate landscape. I think that also gives us a lot of room to maneuver, as Bernt mentioned, on the efficacy side.
Got it. I think that's all the time that we have. Would love any closing remarks that you'd like to give.
No, we're just really excited to see if we can play a meaningful role in a super tough disease like idiopathic pulmonary fibrosis. As Bernt mentioned, I think Bernt and the clinical team have done an amazing job of executing on one of the largest, if not the largest, phase II in IPF, and we're really excited for the readout next year.
Got it. Well, thanks so much for joining us here today.
Thanks, Faisal.
Thanks for having us. Thanks.